JP2010523522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523522A5 JP2010523522A5 JP2010501495A JP2010501495A JP2010523522A5 JP 2010523522 A5 JP2010523522 A5 JP 2010523522A5 JP 2010501495 A JP2010501495 A JP 2010501495A JP 2010501495 A JP2010501495 A JP 2010501495A JP 2010523522 A5 JP2010523522 A5 JP 2010523522A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cor
- formula
- optionally substituted
- conr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical group N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07380088 | 2007-04-02 | ||
| PCT/EP2008/053842 WO2008119792A1 (en) | 2007-04-02 | 2008-03-31 | Pyrrolopyrimidine derivatives as jak3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523522A JP2010523522A (ja) | 2010-07-15 |
| JP2010523522A5 true JP2010523522A5 (OSRAM) | 2011-05-19 |
Family
ID=38475914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501495A Withdrawn JP2010523522A (ja) | 2007-04-02 | 2008-03-31 | Ｊａｋ３阻害剤としてのピロロピリミジン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110160185A9 (OSRAM) |
| EP (1) | EP2142550A1 (OSRAM) |
| JP (1) | JP2010523522A (OSRAM) |
| KR (1) | KR20100015353A (OSRAM) |
| CN (1) | CN101679440A (OSRAM) |
| AR (1) | AR065901A1 (OSRAM) |
| AU (1) | AU2008234822A1 (OSRAM) |
| BR (1) | BRPI0809992A2 (OSRAM) |
| CA (1) | CA2682646A1 (OSRAM) |
| CL (1) | CL2008000946A1 (OSRAM) |
| IL (1) | IL201073A0 (OSRAM) |
| MX (1) | MX2009010595A (OSRAM) |
| PE (1) | PE20090996A1 (OSRAM) |
| RU (1) | RU2009140319A (OSRAM) |
| TW (1) | TW200904442A (OSRAM) |
| WO (1) | WO2008119792A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
| JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| TW201024298A (en) * | 2008-09-23 | 2010-07-01 | Palau Pharma Sa | (R)-3-(N,N-dimethylamino)pyrrolidine derivatives |
| MX2011005597A (es) * | 2008-12-05 | 2011-06-16 | Hoffmann La Roche | Pirrolopirazinil-ureas como inhibidores de cinasas. |
| CN102459267B (zh) * | 2009-06-08 | 2014-11-26 | 武田药品工业株式会社 | 用作jak抑制剂的二氢吡咯并萘啶酮化合物 |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| PL2493895T3 (pl) * | 2009-10-29 | 2017-10-31 | Vectura Ltd | Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3 |
| US9586961B2 (en) | 2010-07-09 | 2017-03-07 | Leo Pharma A/S | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| MX2013001970A (es) | 2010-08-20 | 2013-08-09 | Hutchison Medipharma Ltd | Compuestos de pirrolopirimidina y usos de los mismos. |
| WO2012030924A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
| EP2611448A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| CA2856301C (en) | 2011-11-23 | 2020-10-06 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| ES2827233T3 (es) * | 2013-01-18 | 2021-05-20 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Compuesto heterocíclico de cinco y seis miembros, y método de preparación, composición farmacéutica y uso del mismo |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| US20170137426A1 (en) * | 2014-03-28 | 2017-05-18 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| NO2721710T3 (OSRAM) | 2014-08-21 | 2018-03-31 | ||
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN107801397B (zh) | 2015-02-13 | 2021-07-30 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| CN104876934B (zh) * | 2015-05-12 | 2017-08-11 | 山东大学 | 一种含氮杂环苯基哌啶类化合物及其制备方法与应用 |
| RS59522B1 (sr) | 2015-05-28 | 2019-12-31 | Theravance Biopharma R&D Ip Llc | Naftiridinska jedinjenja kao inhibitori jak kinaze |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| CN110526915B (zh) * | 2018-05-25 | 2022-02-01 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂的制备方法 |
| CA3118488A1 (en) | 2018-11-05 | 2020-05-14 | Avista Pharma Solutions, Inc. | Chemical compounds |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| EP3971190A4 (en) * | 2019-05-17 | 2023-06-14 | Voronoi Inc. | HETEROCYCLICALLY CONDENSED PYRIMIDIDE DERIVATE AND USE THEREOF |
| CN110183471B (zh) * | 2019-05-21 | 2022-02-15 | 江苏大学 | 一种哌嗪类衍生物及制备方法及应用 |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| IL303237A (en) * | 2020-11-27 | 2023-07-01 | Anrui Biomedical Tech Guangzhou Co Ltd | Aminoheteroaryl kinase inhibitors |
| CN116783198B (zh) * | 2020-12-02 | 2025-10-21 | 广东弘烨医药科技有限公司 | 螺环jak抑制剂、含其的药物组合物及其应用 |
| WO2022216097A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 스탠다임 | 신규한 lrrk2 억제제 |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| AU2023298142A1 (en) * | 2022-06-29 | 2025-01-09 | Alcon Inc. | Azetidinyl pyrimidines and uses thereof as jak inhibitors |
| CN118005609B (zh) * | 2022-11-09 | 2025-06-17 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| HRP20000885B1 (hr) * | 1998-06-19 | 2007-03-31 | Pfizer Products Inc. | PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI |
| DE602006004844D1 (de) * | 2005-02-03 | 2009-03-05 | Vertex Pharma | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
-
2008
- 2008-03-31 AU AU2008234822A patent/AU2008234822A1/en not_active Abandoned
- 2008-03-31 WO PCT/EP2008/053842 patent/WO2008119792A1/en not_active Ceased
- 2008-03-31 AR ARP080101351A patent/AR065901A1/es not_active Application Discontinuation
- 2008-03-31 BR BRPI0809992-8A2A patent/BRPI0809992A2/pt not_active IP Right Cessation
- 2008-03-31 US US12/594,228 patent/US20110160185A9/en not_active Abandoned
- 2008-03-31 JP JP2010501495A patent/JP2010523522A/ja not_active Withdrawn
- 2008-03-31 CA CA002682646A patent/CA2682646A1/en not_active Abandoned
- 2008-03-31 CN CN200880015843A patent/CN101679440A/zh active Pending
- 2008-03-31 KR KR1020097020666A patent/KR20100015353A/ko not_active Withdrawn
- 2008-03-31 RU RU2009140319/04A patent/RU2009140319A/ru not_active Application Discontinuation
- 2008-03-31 PE PE2008000586A patent/PE20090996A1/es not_active Application Discontinuation
- 2008-03-31 MX MX2009010595A patent/MX2009010595A/es not_active Application Discontinuation
- 2008-03-31 EP EP08735625A patent/EP2142550A1/en not_active Withdrawn
- 2008-04-01 TW TW097111869A patent/TW200904442A/zh unknown
- 2008-04-01 CL CL200800946A patent/CL2008000946A1/es unknown
-
2009
- 2009-09-21 IL IL201073A patent/IL201073A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523522A5 (OSRAM) | ||
| JP2013510120A5 (OSRAM) | ||
| JP2013512903A5 (OSRAM) | ||
| JP2004531563A5 (OSRAM) | ||
| JP2014507455A5 (OSRAM) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2013545785A5 (OSRAM) | ||
| JP2014506907A5 (OSRAM) | ||
| JP2016516043A5 (OSRAM) | ||
| JP2010504344A5 (OSRAM) | ||
| JP2016523270A5 (OSRAM) | ||
| JP2013523614A5 (OSRAM) | ||
| JP2013509431A5 (OSRAM) | ||
| JP2013532652A5 (OSRAM) | ||
| JP2015506348A5 (OSRAM) | ||
| JP2015537020A5 (OSRAM) | ||
| TW200840567A (en) | Novel oxadiazole compounds | |
| JP2014510774A5 (OSRAM) | ||
| KR20140145615A (ko) | 항바이러스 치료를 위한 화합물 및 방법 | |
| JP2012533546A5 (OSRAM) | ||
| JP2015508092A5 (OSRAM) | ||
| JP2016505010A5 (OSRAM) | ||
| JP2014508804A5 (OSRAM) | ||
| JP2019535723A5 (OSRAM) | ||
| JP2017525699A5 (OSRAM) |